Barnett & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.99M | Sell |
22,931
-441
| -2% | -$97.8K | 3.88% | 5 |
|
|
2025
Q4 | $5.34M | Sell |
23,372
-210
| -0.9% | -$47.8K | 4.3% | 5 |
|
|
2025
Q3 | $5.46M | Sell |
23,582
-215
| -0.9% | -$43.8K | 4.22% | 5 |
|
|
2025
Q2 | $4.42M | Sell |
23,797
-100
| -0.4% | -$18.6K | 3.47% | 6 |
|
|
2025
Q1 | $5.01M | Sell |
23,897
-3,432
| -13% | -$667K | 4.19% | 7 |
|
|
2024
Q4 | $4.86M | Sell |
27,329
-6,139
| -18% | -$1.13M | 3.18% | 10 |
|
|
2024
Q3 | $6.61M | Sell |
33,468
-200
| -0.6% | -$37.3K | 4.37% | 3 |
|
|
2024
Q2 | $5.77M | Hold |
33,668
| – | – | 4.14% | 7 |
|
|
2024
Q1 | $6.13M | Sell |
33,668
-250
| -0.7% | -$43.1K | 4.2% | 5 |
|
|
2023
Q4 | $5.26M | Sell |
33,918
-1,800
| -5% | -$262K | 3.94% | 5 |
|
|
2023
Q3 | $5.32M | Sell |
35,718
-2,716
| -7% | -$399K | 4.16% | 5 |
|
|
2023
Q2 | $5.18M | Sell |
38,434
-795
| -2% | -$117K | 3.85% | 5 |
|
|
2023
Q1 | $6.25M | Buy |
39,229
+260
| +0.7% | +$39.8K | 4.75% | 4 |
|
|
2022
Q4 | $6.3M | Buy |
38,969
+350
| +0.9% | +$53.7K | 4.81% | 3 |
|
|
2022
Q3 | $5.18M | Sell |
38,619
-782
| -2% | -$112K | 4.58% | 3 |
|
|
2022
Q2 | $6.04M | Buy |
39,401
+158
| +0.4% | +$24.1K | 4.83% | 2 |
|
|
2022
Q1 | $6.36M | Sell |
39,243
-77
| -0.2% | -$11.2K | 4.51% | 2 |
|
|
2021
Q4 | $5.32M | Sell |
39,320
-229
| -0.6% | -$27.1K | 3.71% | 4 |
|
|
2021
Q3 | $4.27M | Sell |
39,549
-880
| -2% | -$101K | 3.21% | 8 |
|
|
2021
Q2 | $4.55M | Buy |
40,429
+2,519
| +7% | +$284K | 3.01% | 8 |
|
|
2021
Q1 | $4.1M | Buy |
37,910
+9,333
| +33% | +$998K | 2.18% | 12 |
|
|
2020
Q4 | $3.06M | Buy |
28,577
+1,345
| +5% | +$129K | 1.93% | 16 |
|
|
2020
Q3 | $2.38M | Buy |
27,232
+2,600
| +11% | +$245K | 1.7% | 19 |
|
|
2020
Q2 | $2.42M | Buy |
24,632
+24,532
| +24,532% | +$2.16M | 1.96% | 15 |
|
|
2020
Q1 | $8K | Hold |
100
| – | – | 0.01% | 257 |
|
|
2019
Q4 | $9K | Hold |
100
| – | – | 0.01% | 321 |
|
|
2019
Q3 | $8K | Hold |
100
| – | – | ﹤0.01% | 265 |
|
|
2019
Q2 | $7K | Hold |
100
| – | – | ﹤0.01% | 256 |
|
|
2019
Q1 | $8K | Buy |
+100
| New | +$8.18K | ﹤0.01% | 269 |
|
|
2018
Q1 | – | Sell |
-280
| Closed | -$27K | – | 307 |
|
|
2017
Q4 | $27K | Sell |
280
-220
| -44% | -$20.7K | 0.01% | 220 |
|
|
2017
Q3 | $44K | Hold |
500
| – | – | 0.02% | 195 |
|
|
2017
Q2 | $36K | Hold |
500
| – | – | 0.02% | 228 |
|
|
2017
Q1 | $33K | Hold |
500
| – | – | 0.02% | 206 |
|
|
2016
Q4 | $31K | Hold |
500
| – | – | 0.02% | 237 |
|
|
2016
Q3 | $32K | Buy |
+500
| New | +$32.4K | 0.02% | 238 |
|
Other funds holding ABBV
VCM
VPM
Barnett & Company's ABBV Position: Q1 2026 in Review
Barnett & Company reduced its AbbVie (ABBV) stake by 1.9% in Q1 2026, selling an estimated $97.8K and leaving 22,931 shares worth $4.99M. The position accounts for 3.88% of the portfolio, ranked #5.
Barnett & Company first reported a position in ABBV in Q3 2016 and has held it in 35 quarters since. The position peaked at $6.61M in Q3 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Barnett & Company held 22,931 shares of AbbVie worth $4.99M as of Q1 2026.
- Barnett & Company sold 441 AbbVie shares in Q1 2026, an estimated $97.8K.
- AbbVie made up 3.88% of Barnett & Company's portfolio in Q1 2026, its #5 holding.
- Barnett & Company first reported a position in AbbVie in Q3 2016 and has held it in 35 quarters since.
- Barnett & Company's AbbVie position peaked at $6.61M in Q3 2024.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Barnett & Company's 13F filing for Q1 2026, filed 30 Apr 2026.